Retina Technology

Q3 2026 delivered advances in some closely watched pipeline products.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Physician AI use has more than doubled since 2023—but the next leap in ophthalmology won't come from smarter diagnostic algorithms alone.

Louie Cai, MD, discusses why manual prescreening is so labor-intensive, how the study was designed, and what broader adoption of AI-assisted screening could mean for clinician time, patient satisfaction, and the pace of drug development.

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.

Ultra-widefield imaging reveals early retinal risk in pediatric patients.

Retina cells that sense light falter in Alzheimer’s, potentially derailing sleep and body clocks—pointing to new diagnostic and treatment angles.

StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.

The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.

Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way.

Researchers uncover a DNA repair mechanism in Greenland sharks that preserves their vision for centuries, offering insights into longevity and eye health.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

Advancements in macular laser therapy, emphasizing standardization, precision delivery, and innovative treatment strategies for retinal conditions.

AI revolutionizes ophthalmology with enhanced diagnostics, personalized treatments, and improved surgical precision, offering better patient outcomes and efficient clinical trials.

Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes.